1. Home
  2. XGN vs RFL Comparison

XGN vs RFL Comparison

Compare XGN & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exagen Inc.

XGN

Exagen Inc.

BUY

Current Price

$6.36

Market Cap

253.9M

Sector

Health Care

ML Signal

BUY

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.22

Market Cap

54.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
XGN
RFL
Founded
2002
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
253.9M
54.4M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
XGN
RFL
Price
$6.36
$1.22
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$13.67
N/A
AVG Volume (30 Days)
252.1K
179.1K
Earning Date
11-04-2025
12-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$63,599,000.00
$1,029,000.00
Revenue This Year
$21.76
N/A
Revenue Next Year
$15.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
14.08
47.63
52 Week Low
$2.67
$1.17
52 Week High
$12.23
$3.19

Technical Indicators

Market Signals
Indicator
XGN
RFL
Relative Strength Index (RSI) 28.05 40.17
Support Level $6.20 $1.21
Resistance Level $6.80 $1.35
Average True Range (ATR) 0.35 0.12
MACD 0.05 -0.02
Stochastic Oscillator 13.26 7.11

Price Performance

Historical Comparison
XGN
RFL

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

Share on Social Networks: